Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Effects of intravenous iron therapy on mortality and hospitalization of hemodialysis patients: A prospective cohort study in Korea

Authors
Ryu, HyunjinLee, Jung PyoOh, SoheeCho, Jang-HeeChung, Byung HaChung, SungjinChang, Jae HyunHwang, Jin HoKang, Shin-WookLim, Chun Soo
Issue Date
Feb-2022
Publisher
DUSTRI-VERLAG DR KARL FEISTLE
Keywords
chronic kidney disease; dialysis; iron usage;   intravenous iron;   outcome
Citation
CLINICAL NEPHROLOGY, v.97, no.2, pp 78 - 85
Pages
8
Journal Title
CLINICAL NEPHROLOGY
Volume
97
Number
2
Start Page
78
End Page
85
URI
https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/61703
DOI
10.5414/CN110042
ISSN
0301-0430
Abstract
Iron replacement therapy is necessary for anemia treatment in patients with advanced chronic kidney disease. Intra-venous (IV) iron therapy is an efficient meth-od for iron replacement. However, there are concerns regarding its considerable side effects, including increased risks of infec-tion or major adverse cardiovascular events (MACE). This is a longitudinal study from a multicenter prospective cohort study con-ducted in the Korean end-stage renal dis-ease population. All-cause mortality, death due to infection or MACE, hospitalization due to infection or MACE, and all adverse event of death or hospitalization due to in-fection or MACE were compared according to the iron replacement methods during the first 3 months of enrollment. Among 1,680 hemodialysis patients, 29.3% of patients re-ceived IV iron therapy, and 38% of patients received oral iron therapy. During the me-dian 632 days follow-up, all-cause mortality, mortality or hospitalization due to infection or MACE, and all adverse events did not dif -fer among iron replacement groups. There were significant differences related to the risk of all adverse events among iron re-placement therapies in the log-rank test and univariate Cox regression analysis only in the prevalent dialysis patients; however, the sig-nificance was lost in multivariate Cox regres-sion analysis. Similar results were observed in the 1-year short-term outcome analysis. High-dose IV iron did not increase adverse outcomes. All-cause mortality or all adverse events due to infection or MACE were not higher with the current clinical regimen of IV iron replacement therapy than with oral or no iron therapy in Korean hemodialysis patients.
Files in This Item
There are no files associated with this item.
Appears in
Collections
ETC > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE